Business Context and Reporting Period
The provided filing is Aastrom Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a Vericel Corp. filing. The filing describes a development-stage biotechnology company developing patient-specific cell therapies, principally ixmyelocel-T, for ischemic dilated cardiomyopathy (DCM) and critical limb ischemia (CLI). The filing does not provide a standalone fourth-quarter 2013 income statement or cash-flow summary.
Aastrom was enrolling a 108-patient Phase 2b ixCELL-DCM trial and had stopped enrollment in the Phase 3 REVIVE-CLI trial for strategic and financial reasons. The company completed a 20-for-1 reverse stock split on October 16, 2013; historical share and per-share amounts were retrospectively adjusted.
Key Financial Metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Total revenue | $19,000 | $21,000 | Down $2,000 |
| Total costs and expenses | $20.983 million | $33.781 million | Down $12.798 million |
| Research and development expense | $15.104 million | $26.025 million | Down $10.921 million |
| Selling, general and administrative expense | $5.875 million | $7.750 million | Down $1.875 million |
| Loss from operations | $20.964 million | $33.760 million | Improved by $12.796 million |
| Net loss | $15.622 million | $29.474 million | Improved by $13.852 million |
| Net loss per common share | $6.95 | $16.25 | Improved; loss per share is shown as $(6.95) and $(16.25) |
| Cash at year-end | $8.059 million | $13.638 million | Down $5.579 million |
| Net cash used in operating activities | $19.943 million | $29.545 million | Lower cash burn |
| Warrant liabilities | $2.019 million | $1.995 million | Up $24,000 |
Revenue consisted of approximately $19,000 from cell production sales for investigator-sponsored clinical trials. The company had no meaningful commercial product revenue and stated that it did not expect positive operating cash flow for at least several years unless significant product sales were achieved.
Other income included a $5.337 million non-cash reduction in the fair value of warrant liabilities, compared with $4.248 million in 2012. This accounting gain reduced the reported net loss but did not provide cash.
Total assets were $9.215 million and total liabilities were $5.321 million at December 31, 2013. Debt was immaterial relative to the company’s liquidity: current debt was $6,000 and no long-term debt was reported at year-end. Operating and capital lease commitments totaled approximately $3.865 million, including $895,000 due in 2014.
Material Changes Versus the Prior Comparable Period
- Clinical and operating spending declined primarily because enrollment in REVIVE-CLI was stopped, the company implemented a restructuring, and certain stock-based compensation was reversed. These reductions were partly offset by increased activity in the ixCELL-DCM trial.
- CLI-related research and development expense fell from $21.650 million to $7.223 million, while DCM-related research and development expense increased from $4.366 million to $7.867 million.
- The company recorded a $408,000 one-time restructuring charge in the first quarter of 2013; the remaining restructuring accrual was $21,000 at year-end.
- Cash declined despite $8.169 million of net proceeds from an August 2013 public offering and $4.799 million of net proceeds from the ATM program, reflecting continued operating cash consumption.
- Common shares issued and outstanding increased from approximately 2.189 million at December 31, 2012 to 4.723 million at December 31, 2013, on a post-reverse-split basis, creating dilution risk.
- In August 2013, the company amended its Series B preferred stock agreement and reclassified approximately $38.389 million of preferred stock from mezzanine classification into shareholders’ equity. The filing also corrected a prior-period classification error involving preferred-stock accretion; management deemed the error immaterial to prior periods.
Guidance, Outlook, Risks and Unusual Items
- Management expected to complete ixCELL-DCM enrollment in 2014 and report top-line efficacy results approximately 12 months later. The study’s primary endpoint is major adverse cardiovascular events, with an additional 12-month safety follow-up.
- For REVIVE-CLI, enrollment was halted at 41 patients; follow-up for safety and certain efficacy measures was expected to produce results in the second quarter of 2014.
- The company stated that its $8.059 million of cash was insufficient to sustain operations for one year and that there was substantial doubt about its ability to continue as a going concern. The audited financial statements included an explicit going-concern emphasis and no adjustments for the uncertainty.
- Aastrom expected to require substantial additional capital through equity financing, strategic transactions, grants, collaborations or other sources. Its ATM had approximately $15.074 million of remaining capacity at December 31, 2013, subject to market and trading-volume limitations.
- Subsequent to year-end, the company entered into an agreement with Lincoln Park Capital Fund providing for potential sales of up to $15 million of common stock over 30 months, subject to limitations and a floor price.
- Ixmyelocel-T remained the company’s sole principal product candidate and required successful clinical trials, FDA approval through a Biologics License Application, compliant manufacturing and market acceptance before commercialization.
- Key operational risks included clinical-trial failure or delay, slow patient enrollment, dependence on a centralized Ann Arbor manufacturing facility, reliance on Vention Medical as the sole cell-cassette supplier, reimbursement uncertainty, competition, intellectual-property challenges and the need for future financing.
- The company had approximately $202.105 million of federal net operating loss carryforwards, $50.133 million of state net operating loss carryforwards and $1.600 million of tax credit carryforwards, all subject to potential limitations under Section 382 and fully offset by a valuation allowance.
Most Important Facts for an Investor to Verify
- Verify the issuer identity: the supplied filing is for Aastrom Biosciences, Inc., whereas the request identifies Vericel Corp.
- Verify current liquidity, financing proceeds and operating runway, given the explicit going-concern warning and the company’s stated need for additional capital.
- Verify the status and results of the ixCELL-DCM and amended REVIVE-CLI clinical programs, including regulatory plans and subsequent events after March 13, 2014.
- Reconcile dilution from the ATM, August 2013 offering, warrants, options and Series B preferred stock, including accrued preferred dividends and conversion terms.
- Review the non-cash warrant fair-value gain and preferred-stock reclassification separately from operating performance and cash generation.
- Confirm manufacturing and supply continuity, particularly the centralized Ann Arbor facility and exclusive Vention Medical cell-cassette arrangement.